WO2001032616A2 - Derives d'oxetanone - Google Patents

Derives d'oxetanone Download PDF

Info

Publication number
WO2001032616A2
WO2001032616A2 PCT/US2000/029641 US0029641W WO0132616A2 WO 2001032616 A2 WO2001032616 A2 WO 2001032616A2 US 0029641 W US0029641 W US 0029641W WO 0132616 A2 WO0132616 A2 WO 0132616A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
compound
substituted
alkylthio
Prior art date
Application number
PCT/US2000/029641
Other languages
English (en)
Other versions
WO2001032616A3 (fr
Inventor
John Jason Gentry Mullins
Original Assignee
John Jason Gentry Mullins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/431,551 external-priority patent/US6235305B1/en
Application filed by John Jason Gentry Mullins filed Critical John Jason Gentry Mullins
Priority to AU12381/01A priority Critical patent/AU1238101A/en
Priority to CA002358921A priority patent/CA2358921A1/fr
Priority to KR1020017008352A priority patent/KR20010108059A/ko
Priority to IL14404500A priority patent/IL144045A0/xx
Priority to EP00973938A priority patent/EP1144377A4/fr
Priority to MXPA01006755A priority patent/MXPA01006755A/es
Priority to JP2001534769A priority patent/JP2003524685A/ja
Publication of WO2001032616A2 publication Critical patent/WO2001032616A2/fr
Priority to US09/901,166 priority patent/US20020016307A1/en
Publication of WO2001032616A3 publication Critical patent/WO2001032616A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones

Definitions

  • This invention relates to novel oxetanone derivative compounds and processes for producing such derivatives which are useful as lipase inhibitors. Further the mvention relates to processes for producing salts and for producing pharmaceutical compositions compounds comprising at least one such oxetanone derivative or salt, as well as methods for using such compounds and compositions for inhibiting lipases. In one aspect the invention relates to lipase inhibitors which include on the same molecule an oxetanone derivative portion capable of inhibiting a lipase and a non- absorbable moiety such a polysaccharide, which are covalently linked or are in the form of a salt.
  • the non-absorbable moiety is lipophilic and will associate with oils or fats.
  • An absorbable oxetanone lipase inhibitor may be rendered non-absorbable by covalent linking it directly or indirectly to a non-absorbable moiety and thereby producing a novel non-absorbable lipase inhibitor.
  • oxetanones Some lipase-inhibiting oxetanones and intermediates for making them are well known. See for example, U.S. patents 5,931,463, 4,189,438 and 4,202,824. However, there is a need for improved oxetanones that are have low toxicity and are essentially not absorbable by the digestive system of mammals such as dogs, cats, non-human primates and human primates.
  • Lipase inhibitors such as esterastin (see U.S. 4,189,438), tetrahydroesterastin (3 ,5-hydroxy-2hexadeca-7, 10-dienoic 1 ,3-lactone), 3 ,5-dihydroxy-2-hexylhexadeca- 7,10-dienoic 1,3-lactone, 3,5-di-hydroxy-2-hexylhexadecanoic 1,3-lactone, and the like, are well-known as lipase inhibitors and as pancreatic cholesterol esterase inhibitors.
  • lipase inhibitors are, ter alia, also substantially orally active as immunosuppressants (see U.S. 4,189,438 and U.S.
  • Such lipase inhibitor compounds are 3,5 dihydroxy 1,3 lactone derivative compounds, wherein the 5 hydroxyl group may be esterified at the 5 position or is hydrolyzed to the free hydroxyl group.
  • a popular lipase inhibiting compound which is substantially non-absorbable is known as Orlistat ((2S,3S,5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3- hydroxy-hexadecanoic 1,3 acid lactone, see U.S. 5,643,874).
  • This compound is a steric isomer derivative of tetrahydroesteratin and its 5 -hydroxyl group is esterified with a [S-2-formamido-4-methyl-valeryloxy] group.
  • Orlistat has been used to inhibit Upases in the body and thereby prevent the absorption of dietary fat.
  • Orlistat taken before consuming a fat-containing meal (or up to one hour after eating such a meal), up to one-third of the fat eaten at a given meal will not be absorbed by the average person and utilized as dietary fat calories.
  • the undigested fat passes directly through the digestive system as an oil and is eliminated from the bowel in its oily undigested form.
  • Certain polysaccharides are non-absorbable and some polysaccharides have the side benefit of reducing lipid absorption by the body.
  • Defatted rice germ polysaccharides and sulfated polysaccharides are also lipase inhibitors, which are high molecular weight compounds that do not appear to have any lactone moieties and seem to work by a different mechanism, binding the lipase and removing it from the digestive system when they are discharged from the digestive system.
  • the super fiber Chitosan which is a deacylated polysaccharide derived from shellfish chitan, has an ability to absorb fat and cholesterol, particularly in combination with vitamin C. Chitosan compositions may actually absorb up to 6 to 8 times their weight in fat and oils.
  • polysaccharide from shellfish is similar to crude cellulose plant fiber, it has the ability to significantly bind fat in the digestive system as compared to plant fiber. Further, since polysaccharides, including those which do not preferentially bind oils over water, are not absorbed by the digestive systems of animals such as humans, non-human primates, dogs and cats, there is no caloric value to such polysaccharides and they pass through the such digestive systems unabsorbed and substantially intact.
  • non-absorbable polysaccharides are polysaccharides having a molecular weight of greater than 8 kDa such as dextrans, molecular microcrystalline cellulose, wheat bran, oat bran, defatted rice germ, alginic acid, pectin, amylopectin, chitin, crude cellulose, argar, chitosan and the like.
  • the present invention relates to novel derivatives of lipase inhibitors which are non-absorbable compounds comprising at least one lipase inhibitor moiety and at least one non-absorbable polymeric moiety in the same molecule or salt.
  • the lipase inhibitor moiety is preferably present in the non- absorbable compound in a weight ratio of from about 1 : 10 to about 1 :60 with respect to the weight of the polymeric moiety, preferably from about 1 :20 to about 1 :40, and more preferably from about 1:25 to 1:35.
  • such lipase inhibitors comprise at least one lipase inhibitor moiety (or moieties) linked directly or indirectly to such a polymeric moiety.
  • the invention also includes pharmaceutical compositions comprising an effective amount of such lipase inhibitors in combination with a pharmaceutically acceptable carrier or diluent, which compositions may further comprise an effective amount of a lipophilic, non-absorbable biocompatible, pharmaceutically acceptable oil absorbing polymer.
  • the present invention relates to novel salts of non-absorbable lipase inhibitors and a non-absorbable biocompatible, pharmaceutically acceptable oil absorbing polymer.
  • the invention also includes pharmaceutical compositions comprising an effective amount of such lipase inhibitors in combination with a pharmaceutically acceptable carrier or diluent, which compositions may further comprise an effective amount of a lipophilic, non-absorbable biocompatible, pharmaceutically acceptable oil absorbing polymer.
  • the present invention relates to novel non-absorbable derivatives of a 1 ,3 oxetanone lipase inhibitor, which include at least one 1 ,3 oxetanone lipase inhibiting moiety that is covalently or non-covalently linked to a non-absorbable biocompatible, pharmaceutically acceptable polymer moiety to provide a novel lipase inhibitor compound.
  • Preferred compounds have the dual function of inhibiting lipases and absorbing fat, in that the non-absorbable biocompatible, pharmaceutically acceptable polymer moiety of the novel lipase inhibitor will bind to fat, carry the bound fat with it through portions of the digestive system and cause the non-absorbed fat to be eliminated removed from the digestive system as undigested fat.
  • the 1,3 oxetanone moiety that is derivatized directly or indirectly with the polymer moiety according to the mvention may be initially an absorbable or non-absorbable moiety and is derivatized by directly or indirectly linking it to the polymer moiety to form a novel non-absorbable lipase inhibitor, preferably at the 5 hydroxyl position of a 1,3 oxetanone moiety.
  • the invention provides compounds having either non- covalent linkages of such two moieties or covalent linkages that are hydrolyzed or digested in the digestive system, providing that the lipase inhibiting 1,3 oxetanone derivative moiety that is released in the digestive system is substantially non- absorbable.
  • the invention provides compounds having either a non-covalent linkage of such two moieties or a covalent linkage that is not hydrolyzed or digested in the digestive system, whereby the lipase inhibiting 1,3 oxetanone derivative moiety remains linked to the polymer moiety via such non-covalent or covalent linkage and is not released in the digestive system.
  • an absorbable lipases such as esterastin moiety, tetrahydroestrastin, or a similar moiety
  • Prefe ⁇ ed absorbable lipase inhibitor moieties that are rendered non-absorbable by such coupling include at least one lipase inhibitor which is a member selected from the group consisting of esterastin, tetrahydro-esterastin (3,5- hydroxy-2-hexadeca-7, 10-dienoic 1 ,3-lactone), 3 ,5-dihydroxy-2-hexylhexadeca-7, 10- dienoic 1,3-lactone, 3,5-di-hydroxy-2-hexylhexadecanoic 1,3-lactone, and the like.
  • such lipase inhibitor is coupled to a non-absorbable biocompatible, pharmaceutically acceptable polymer moiety, such as a polysaccharide, to render the lipase non-absorbable by the digestive system of an animal such as a dog, cat, non- human primate or humans.
  • a non-absorbable biocompatible, pharmaceutically acceptable polymer moiety such as a polysaccharide
  • Particularly prefe ⁇ ed polysaccharides have at least one member selected from the group consisting of dextrans, molecular microcrystalline cellulose, wheat bran, oat bran, defatted rice germ, alginic acid, pectin, amylopectin, chitin, crude cellulose, argar, chitosan, a chitosan methylbenzoic acid ester ether derivative, and the like.
  • lipase inhibitors bound via a derivatized group on the lipase such as a derivatized nitrogen, acid or alcohol group to a group on the polymer moiety such as a derivatized alcohol, acid or amino group.
  • a diether bridge is formed between the lipase inhibitor and the moiety, wherein the bridge is derived from an alcohol group on the lipase and an alcohol group on the moiety, each reacting with an etherizing bridging group.
  • the present invention relates to pharmaceutical compositions comprising a lipase inhibiting effective amount of at least one lipase inhibitor which is coupled to a digestively non-absorbable moiety.
  • a lipase inhibiting effective amount of at least one lipase inhibitor which is coupled to a digestively non-absorbable moiety.
  • a lipases coupled to a non-absorbable biocompatible, pharmaceutically acceptable polymer moiety, such as a polysaccharide, wherein the lipase is essentially non-absorbable by the digestive system of an animal such as a dog, cat, non-human primate or humans.
  • the present invention relates to a method for treating adiposity or obesity by administering to a patient before a fat-contain meal, or up to one hour after such a meal is consumed, an amount of at least one lipase inhibitor which is bound to a non-absorbable polymer moiety in an amount effective to inhibit the absorption of up to one-third of the dietary fat in such a meal .
  • a prefe ⁇ ed method comprises administering at one lipase inhibitor which is a member selected from the group consisting of esterastin, tetrahydro-esterastin (3,5-hydroxy- 2hexadeca-7, 10-dienoic 1 ,3-lactone), 3 ,5-dihydroxy-2-hexylhexadeca-7, 10-dienoic 1,3-lactone, 3,5-di-hydroxy-2-hexylhexadecanoic 1,3-lactone, and the like, wherein such lipase inhibitor is coupled to a non-absorbable biocompatible, pharmaceutically acceptable polymer moiety, such as a polysaccharide, to render the lipase non- absorbable by the digestive system of an animal such as a dog, cat, non-human primate or humans.
  • lipase inhibitor which is a member selected from the group consisting of esterastin, tetrahydro-esterastin (3,5-hydroxy- 2hexadeca-7, 10-die
  • Particularly prefe ⁇ ed polysaccharides are at least one member selected from the group consisting of dextrans, molecular microcrystalline cellulose, wheat bran, oat bran, defatted rice germ, alginic acid, pectin, amylopectin, chitin, crude cellulose, argar, chitosan and the like.
  • Particularly prefe ⁇ ed bound lipase inhibitors are lipase inhibitors bound via a derivatized nitrogen, acid or alcohol group to a derivatized alcohol, acid or amino group on the polymer moiety.
  • a diether terminated bridge, or a terminal ether/terminal ester bridge, between the lipase inhibitor moiety and the polymer moiety which is derived from an alcohol group on the lipase inhibitor moiety and an alcohol group on the polymer moiety, respectively reacting with a bridging group is a prefe ⁇ ed coupling of the lipase inhibitor to the moiety.
  • Another prefe ⁇ ed bridge between the lipase inhibitor moiety and the polymer moiety includes at least one ether bridge formed from an alcohol group on the polymer moiety and at least one carboxamide bond. Further prefe ⁇ ed are compound wherein at least one amino acid derivative is located in the bridge, and is bound directly or indirectly to the 5 hydroxyl position on the 1 ,3 oxetanone moiety via an ester linkage.
  • the prefe ⁇ ed compounds also include their pharmaceutically acceptable isomers, hydrates, solvates, salts and prodrug derivatives.
  • alkenyl refers to a trivalent straight chain or branched chain unsaturated aliphatic radical.
  • alkinyl (or “alkynyl”) refers to a straight or branched chain aliphatic radical that includes at least two carbons joined by a triple bond. If no number of carbons is specified alkenyl and alkinyl each refer to radicals having from 2-12 carbon atoms.
  • alkyl refers to saturated aliphatic groups including straight-chain, branched-chain and cyclic groups having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms.
  • cycloalkyl refers to a mono-, bi-, or tricyclic aliphatic ring having 3 to 14 carbon atoms and preferably 3 to 7 carbon atoms.
  • bridging group refers to a bifunctional chain or spacer group capable of reacting with one or more functional groups on a lipase inhibitor compound and then react with a second same or different functional group on a polymer compound in order to form a linked structure or conjugate between the two compounds.
  • the bond formed between the bridging group and each of the two moieties is preferably of a type that is resistant to cleavage by the digestive environment when the linked lipase moiety would be absorbable upon cleavage of the bond.
  • the bridging group is of the formula X-R-X, wherein R is a member selected from a straight-chained or branched alkyl group, a straight-chained or branched alkenyl group, a straight-chained or branched alkynyl group, a mono acyl group, a diacyl group and the like, which R portion of the chain may include a cycloalkyl or an aryl group, and X is a functionally reactive group such as a halogen, or acid group, under special reaction conditions as described hereinafter.
  • bridging groups form a diether, diacyl or ether/acyl bridge that is resistant to cleavage by the digestive environment.
  • bridging groups that are cleaved by the digestive group to release an essentially non-absorbable lipase inhibitor are prefe ⁇ ed.
  • alkylene dichloride bridging group forming compounds are dichloromethane, 1 ,2-dichloroethane, 1,2- and 1,3-dichloropropane, 1,2-, 1,3- and 1 ,4-dichlorobutane, and the like.
  • acyldichloride bridging group forming compounds are oxalic acid dichloride, malonic acid dichloride, succinic acid dichloride, glutaric acid dichloride, adipic acid dichloride, pimelic acid dichloride, suberic acid dichloride, fumaric acid dichloride, malic acid dichloride, glutamic acid dichloride, terephthalic acid dichloride, isophthalic acid dichloride, haloalkylbenzoic acid, and the like.
  • Other such bridging group reagents are compounds such as epichlorhydrin, phosphorus oxychloride, and diphosphoryl tetrachloride, and the like.
  • the terms "carbocyclic ring structure " and " C 3 _ ⁇ 6 carbocyclic mono, bicyclic or tricyclic ring structure” or the like are each intended to mean stable ring structures having only carbon atoms as ring atoms wherein the ring structure is a substituted or unsubstituted member selected from the group consisting of: a stable monocyclic ring which is aromatic ring ("aryl") having six ring atoms; a stable monocyclic non-aromatic ring having from 3 to 7 ring atoms in the ring; a stable bicyclic ring structure having a total of from 7 to 12 ring atoms in the two rings wherein the bicyclic ring structure is selected from the group consisting of ring structures in which both of the rings are aromatic, ring structures in which one of the rings is aromatic and ring structures in which both of the rings are non-aromatic; and a stable tricyclic ring structure having a total of from 10 to 16 atoms in the three
  • non-aromatic rings when present in the monocyclic, bicyclic or tricyclic ring structure may independently be saturated, partially saturated or fully saturated.
  • carbocyclic ring structures include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), 2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).
  • the ring structures described herein may be attached to one or more indicated pendant groups via any carbon atom which results in a stable structure.
  • substituted as used in conjunction with carbocyclic ring structures means that hydrogen atoms attached to the ring carbon atoms of ring structures described herein may be substituted by one or more of the substituents indicated for that structure if such substitution(s) would result in a stable compound.
  • aryl which is included with the term “carbocyclic ring structure” refers to an unsubstituted or substituted aromatic ring, substituted with one, two or three substituents selected from loweralkoxy, loweralkyl, loweralkylamino, hydroxy, halogen, cyano, hydroxyl, mercapto, nitro, thioalkoxy, carboxaldehyde, carboxyl, carboalkoxy and carboxamide, including but not limited to carbocyclic aryl, heterocyclic aryl, and biaryl groups and the like, all of which may be optionally substituted.
  • Prefe ⁇ ed aryl groups include phenyl, halophenyl, loweralkylphenyl, napthyl, biphenyl, phenanthrenyl and naphthacenyl.
  • arylalkyl which is included with the term “carbocyclic aryl” refers to one, two, or three aryl groups having the number of carbon atoms designated, appended to an alkyl group having the number of carbon atoms designated. Suitable arylalkyl groups include, but are not limited to, benzyl, picolyl, naphthylmethyl, phenethyl, benzyhydryl, trityl, and the like, all of which may be optionally substituted.
  • heterocyclic ring or “heterocyclic ring system” is intended to mean a substituted or unsubstituted member selected from the group consisting of stable monocyclic ring having from 5-7 members in the ring itself and having from 1 to 4 hetero ring atoms selected from the group consisting of N, O and S; a stable bicyclic ring structure having a total of from 7 to 12 atoms in the two rings wherein at least one of the two rings has from 1 to 4 hetero atoms selected from N, O and S, including bicyclic ring structures wherein any of the described stable monocyclic heterocyclic rings is fused to a hexane or benzene ring; and a stable tricyclic heterocyclic ring structure having a total of from 10 to 16 atoms in the three rings wherein at least one of the three rings has from 1 to 4 hetero atoms selected from the group consisting of N, O and S.
  • heterocyclic ring or “heterocyclic ring system” include aromatic rings, as well as non-aromatic rings which can be saturated, partially saturated or fully saturated non-aromatic rings.
  • heterocyclic ring system includes ring structures wherein all of the rings contain at least one hetero atom as well as structures having less than all of the rings in the ring structure containing at least one hetero atom, for example bicyclic ring structures wherein one ring is a benzene ring and one of the rings has one or more hetero atoms are included within the term "heterocyclic ring systems” as well as bicyclic ring structures wherein each of the two rings has at least one hetero atom.
  • the ring structures described herein may be attached to one or more indicated pendant groups via any hetero atom or carbon atom which results in a stable structure.
  • substituted means that one or more of the hydrogen atoms on the ring carbon atom(s) or nitrogen atom(s) of the each of the rings in the ring structures described herein may be replaced by one or more of the indicated substituents if such replacement(s) would result in a stable compound.
  • Nitrogen atoms in a ring structure may be quaternized, but such compounds are specifically indicated or are included within the term "a pharmaceutically acceptable salt” for a particular compound.
  • the total number of O and S atoms in a single heterocyclic ring is greater than 1 , it is prefe ⁇ ed that such atoms not be adjacent to one another.
  • Examples of monocylic and bicyclic heterocylic ring systems, in alphabetical order, are acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2- dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, ind
  • Prefe ⁇ ed heterocyclic ring structures include, but are not limited to, pyridinyl, furanyl, thienyl, py ⁇ olyl, pyrazolyl, py ⁇ olidinyl, imidazolyl, indolyl, benzimidazolyl, lH-indazolyl, oxazolinyl, or isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocylic ring structures.
  • aromatic heterocyclic ring system has essentially the same definition as for the monocyclic and bicyclic ring systems except that at least one ring of the ring system is an aromatic heterocyclic ring or the bicyclic ring has an aromatic or non-aromatic heterocyclic ring fused to an aromatic carbocyclic ring structure.
  • halo or halogen as used herein refer to Cl, Br, F or I substituents.
  • haloalkyl refers to an aliphatic carbon radicals having at least one hydrogen atom replaced by a Cl, Br, F or I atom, including mixtures of different halo atoms.
  • Trihaloalkyl includes trifluoromethyl and the like as prefe ⁇ ed radicals, for example.
  • methylene refers to -CH2-.
  • salts includes salts of compounds derived from the combination of a compound and an organic or inorganic acid. These compounds are useful in both free base and salt form. In practice, the use of the salt form amounts to use of the base form; both acid and base addition salts are within the scope of the present invention.
  • “Pharmaceutically acceptable acid addition salt” refers to salts retaining the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicyclic acid and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like
  • organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid
  • “Pharmaceutically acceptable base addition salts” include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly prefe ⁇ ed are the ammonium, potassium, sodium, calcium and magnesium salts.
  • Salts derived from pharmaceutically acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, polyamine resins and the like.
  • Particularly prefe ⁇ ed organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethamine, dicyclohexylamine, choline, and
  • Bio property for the purposes herein means an in vivo effector or antigenic function or activity that is directly or indirectly performed by a compound of this invention that are often shown by in vitro assays. Effector functions include receptor or ligand binding, any enzyme activity or enzyme modulatory activity, any carrier binding activity, any hormonal activity, any activity in promoting or inhibiting adhesion of cells to an extracellular matrix or cell surface molecules, or any structural role. Antigenic functions include possession of an epitope or antigenic site that is capable of reacting with antibodies raised against it.
  • carbon atoms bonded to four non-identical substituents are asymmetric. Accordingly, the compounds may exist as diastereoisomers, enantiomers or mixtures thereof.
  • the syntheses described herein may employ racemates, enantiomers or diastereomers as starting materials or intermediates. Diastereomeric products resulting from such syntheses may be separated by chromatographic or crystallization methods, or by other methods known in the art. Likewise, enantiomeric product mixtures may be separated using the same techniques or by other methods known in the art.
  • Each of the asymmetric carbon atoms when present in the compounds of this invention, may be in one of two configurations (R or S) and both are within the scope of the present invention.
  • the present invention relates to novel derivatives of lipase inhibitors which are non-absorbable and have a lipase inhibitor moiety and polymeric moiety in the same molecule.
  • the invention also includes pharmaceutical compositions comprising an effective amount of such lipase inhibitors in combination with a pharmaceutically acceptable carrier or diluent, and may further comprise an effective amount of a lipophilic, non-absorbable biocompatible, pharmaceutically acceptable oil absorbing polymer.
  • the lipase inhibitor moiety is present in a weight ratio of from about 1 : 10 to about 1 :60 with respect to the weight of the polymeric moiety, preferably from about 1 :20 to about 1 :40, and more preferably from about 1 :25 to 1 :35.
  • such lipase inhibitors comprise at least one lipase inhibitor moiety (or moieties) linked directly or indirectly to such polymeric moiety.
  • the present invention relates to novel salts of non-absorbable lipase inhibitors and a non-absorbable biocompatible, pharmaceutically acceptable oil absorbing polymer.
  • the invention also includes pharmaceutical compositions comprising an effective amount of such lipase inhibitors in combination with a pharmaceutically acceptable carrier or diluent, which compositions may further comprise an effective amount of a lipophilic, non-absorbable biocompatible, pharmaceutically acceptable oil absorbing polymer.
  • the present invention relates to novel non-absorbable derivatives of a 1,3 oxetanone lipase inhibitor, which include at least one 1,3 oxetanone lipase inhibiting moiety that is covalently or non-covalently linked to a non-absorbable biocompatible, pharmaceutically acceptable polymer moiety to provide a novel lipase inhibitor compound.
  • Prefe ⁇ ed compounds have the dual function of inhibiting lipases and absorbing fat, in that the non-absorbable biocompatible, pharmaceutically acceptable polymer moiety of the novel lipase inhibitor will bind to fat, carry the bound fat with it through portions of the digestive system and cause the non-absorbed fat to be eliminated removed from the digestive system as undigested fat.
  • the 1,3 oxetanone moiety that is derivatized directly or indirectly with the polymer moiety according to the invention may be initially an absorbable or non-absorbable moiety and is derivatized by directly or indirectly linking it to the polymer moiety to form a novel non-absorbable lipase inhibitor, preferably at the 5 hydroxyl position of a 1,3 oxetanone moiety.
  • the invention provides compounds having either non- covalent linkages of such two moieties or covalent linkages that are hydrolyzed or digested in the digestive system, providing that the lipase inhibiting 1,3 oxetanone derivative moiety that is released in the digestive system is substantially non- absorbable.
  • the invention provides compounds having either a non-covalent linkage of such two moieties or a covalent linkage that is not hydrolyzed or digested in the digestive system, whereby the lipase inhibiting 1 ,3 oxetanone derivative moiety remains linked to the polymer moiety via such non-covalent or covalent linkage and is not released in the digestive system.
  • an absorbable lipases such as esterastin moiety, tetrahydroestrastin, or a similar moiety
  • Prefe ⁇ ed absorbable lipase inhibitor moieties that are rendered non-absorbable by such coupling include at least one lipase inhibitor which is a member selected from the group consisting of esterastin, tetrahydro-esterastin (3,5- hydroxy-2-hexadeca-7, 10-dienoic 1 ,3-lactone), 3 ,5-dihydroxy-2-hexylhexadeca-7, 10- dienoic 1,3-lactone, 3,5-di-hydroxy-2-hexylhexadecanoic 1,3-lactone, and the like.
  • such lipase inhibitor is coupled to a non-absorbable biocompatible, pharmaceutically acceptable polymer moiety, such as a polysaccharide, to render the lipase non-absorbable by the digestive system of an animal such as a dog, cat, non- human primate or humans.
  • a non-absorbable biocompatible, pharmaceutically acceptable polymer moiety such as a polysaccharide
  • Particularly prefe ⁇ ed polysaccharides have at least one member selected from the group consisting of dextrans, molecular microcrystalline cellulose, wheat bran, oat bran, defatted rice germ, alginic acid, pectin, amylopectin, chitin, crude cellulose, argar, chitosan, a chitosan methylbenzoic acid ester ether derivative, and the like.
  • lipase inhibitors bound via a derivatized group on the lipase such as a derivatized nitrogen, acid or alcohol group to a group on the polymer moiety such as a derivatized alcohol, acid or amino group.
  • a diether bridge is formed between the lipase inhibitor and the moiety, wherein the bridge is derived from an alcohol group on the lipase and an alcohol group on the moiety, each reacting with an etherizing bridging group.
  • oxetanone moiety is derivatized to provide an amino group which is further derivatized to form a carboxamide group, followed by linking the carboxamide group to an acid or alcohol group on the polymer moiety via a bridging group, which polymer moiety may have been derivativized in order to provide such an acid or alcohol group for attachment. Examples of such attachments are illustrated below by prefe ⁇ ed embodiments of the invention.
  • a diether terminated bridge, or a terminal ether/terminal ester bridge, between the lipase inhibitor moiety and the polymer moiety which is derived from an alcohol group on the lipase inhibitor moiety and an alcohol group on the polymer moiety, respectively reacting with a bridging group is a prefe ⁇ ed coupling of the lipase inhibitor to the moiety.
  • Another prefe ⁇ ed bridge between the lipase inhibitor moiety and the polymer moiety includes at least one ether bridge formed from an alcohol group on the polymer moiety and at least one carboxamide bond. Further prefe ⁇ ed are compound wherein at least one amino acid derivative is located in the bridge, and is bound directly or indirectly to the 5 hydroxyl position on the 1 ,3 oxetanone moiety via an ester linkage.
  • the prefe ⁇ ed compounds also include their pharmaceutically acceptable isomers, hydrates, solvates, salts and prodrug derivatives.
  • a prefe ⁇ ed aspect of the present invention relates to novel oxetanone derivatives of the formula I, as follows: wherein: t is an integer from 0 to 1
  • X-O-Q is an ether linkage wherein:
  • X of the ether linkage is a bridging group
  • Q of the ether linkage is a polysaccharide of a sufficient molecular weight or property that such polysaccharide is not absorbed by the digestive system of a mammal such as a dog, cat, non-human primate or a human primate, which polysaccharide is further defined below
  • R is a member selected from the group consisting of: a straight or branched chained C 1-17 -alkyl group which is saturated or optionally interrupted by up to eight double or triple bonds; a straight or branched chained C ⁇ -17 -alkyl group which is saturated or optionally interrupted by one or more members selected from the group consisting of an oxygen atom, a sulfur atom, a sulfonyl group or a sulfmyl group; a straight or branched chained C ⁇ -17 -alkyl group which is saturated or optionally interrupted by up to eight double or triple bonds and is interrupted in
  • R 1 is a member selected from the group consisting of: Hydrogen, Ar, Ar- C ⁇ - 5 -alkyl and
  • R 2 is
  • R 3 is a member selected from the group consisting of: a straight or branched chained C ⁇ _ ⁇ -alkyl group which is saturated or optionally interrupted by up to eight double or triple bonds; a straight or branched chained C ⁇ _ ⁇ -alkyl group which is saturated or optionally interrupted by one or more members selected from the group consisting of an oxygen atom, a sulfur atom, a sulfonyl group or a sulfmyl group; a straight or branched chained C .
  • - ⁇ -alkyl group which is saturated or optionally interrupted by up to eight double or triple bonds and is interrupted in a position other than alpha to an unsaturated carbon atom by one or more members selected from the group consisting of an oxygen atom, a sulfur atom, a sulfonyl group or a sulfmyl group atoms; phenyl substituted by 0-4 members selected from the group consisting of -C ⁇ _ 6 -alkyloxy-C ⁇ _6-alkyl, -C ⁇ _ 6 -alkylthio-C ⁇ - 6 -alkyl, -C ⁇ _ 6 -alkyl-OH and -C ⁇ - 6 - alkyl-SH; benzyl substituted by 0-4 members selected from the group consisting of
  • 6 -alkyl-SH phenylthiophenylene substituted by 0-6 members selected from the group consisting of -C i . 6 -alkyloxy-C i _6-alkyl, -C i _6-alkylthio-C i _ 6 -alkyl, -C i _ 6 -alkyl-
  • R 4 -R 10 are each independently a member selected from the group consisting of: hydrogen and C ⁇ - 6 -alkyl;
  • n is an integer of 0-3;
  • a prefe ⁇ ed compound according to formula I is a compound wherein X is a member selected from the group consisting of:
  • X a is a member selected from the group consisting of:
  • Ci- ⁇ -alkylene group which is saturated or optionally interrupted by up to eight double or triple bonds
  • the present invention relates to novel oxetanone derivatives wherein n of the above formula is zero to provide compounds of the formula:
  • X, t, Q, R, R 1 , R 2 and R 3 are defined as above, and isomers, salts, hydrates, solvates and prodrug derivatives thereof.
  • More prefe ⁇ ed are such compounds wherein R is -(CH 2 ) 5 -CH and R 3 is a member selected from the group consisting of -(CH 2 ) ⁇ o-CH 3 and
  • R la is independently defined the same as defined for R 1
  • R 2a is independently defined the same as for R 2
  • m is a integer from 0 to 10, preferably from 0-5, and more prefe ⁇ ed from 0-2
  • z is an integer from 1 to 20, preferably 2 to 10, and more preferably, 2-4, and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
  • the present invention relates to such novel oxetanone derivatives of formula 1 having the following formula:
  • X, Q, R, and R are defined as above, and isomers, salts, hydrates, solvates and prodrug derivatives thereof.
  • z is a integer from 0 to 10, preferably from 0-5, and more prefe ⁇ ed from 0-2.
  • R is independently defined the same as defined for R
  • R a is independently defined the same as for R
  • m is a integer from 0 to 10, preferably from 0-5, and more preferred from 0-2, and wherein z is an integer from 1 to 20, preferably 2 to 10, and more preferably, 2-4, and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
  • z is a integer from 0 to 10, preferably from 0-5, and more prefe ⁇ ed from 0-2,
  • X is a member selected from the group consisting of:
  • X is a member selected from the group consisting of:
  • X is a member selected from the group consisting of:
  • Particularly prefe ⁇ ed Q groups for the above compounds are non-absorbable biocompatable, pharmaceutically acceptable polymers, such as a polysaccharide, which are preferably lipophilic and bind to fat and are non-absorbable by the digestive system of an animal such as a dog, cat, non-human primate or humans.
  • Particularly prefe ⁇ ed polysaccharides have at least one member selected from the group consisting of dextrans, molecular microcrystalline cellulose, wheat bran, oat bran, defatted rice germ, alginic acid, pectin, amylopectin, chitin, crude cellulose, argar, chitosan and the like.
  • Particularly prefe ⁇ ed Q groups have an alcohol, acyl group or amino group, or can be derivitized to present such an alcohol, acyl or amino group, which can be bound to the R moiety or the X-R-X group
  • at least one and or two ether bridges can be formed between a lipase inhibitor moiety and the polymer moiety via an X-R-X bridge, wherein the bridge is derived from an alcohol group or amine group on the lipase and an alcohol group, acyl group or amino group on the Q group.
  • Q groups which are chitosan derivatives that have been modified by an ether group which is terminated by an organic acid group.
  • modified chitosan Q groups wherein the organic acyl groups are independently a straight or branched chained alkanoyl group.
  • modified chitosan Q groups wherein the polarity resulting from the modification of chitosan with organic acyl groups allows the modified chitosan to absorb both lipids and water and to form a substantially homogenous gel with oil and water.
  • the Q group is a chitosan compound modified with a sufficient number of organic acyl groups to cause the modified chitosan to absorb or associate both lipids and water and to form a substantially homogenous gel with oil and water.
  • the number of organic acyl groups present on the modified chitosan chains are present in a molar ratio from 1 to 8 times the number of the molar ratio of esterified lipase inhibitor alcohol groups, and more preferably a ratio from 2 to 5 times, and most preferably a ratio of from 3 to 4 times the number of esterified lipase inhibitor alcohol groups.
  • the lipase inhibitor compounds, polymer moieties and bridging groups of the present invention may be synthesized or readily obtained from commercially available sources.
  • Polymer bridging groups, bridge coupling processes and compound purification methods are described and referenced in standard textbooks, particularly the coupling of alcohol groups via diether bridges, ether/ester bridges, ether/ketone bridges and the like.
  • Standard polymer textbooks reference typical bifimctional bridging groups and coupling procedures.
  • Reactions are carried out in standard laboratory glassware and reaction vessels under reaction conditions of standard temperature and pressure, except where otherwise indicated.
  • the functional groups may be protected by blocking groups to prevent cross reaction during the coupling procedure.
  • blocking groups Examples of suitable blocking groups and their use are described in "The Peptides: Analysis, Synthesis, Biology", Academic Press, Vol. 3 (Gross, et al., Eds., 1981) and Vol. 9 (1987), the disclosures of which are incorporated herein by reference.
  • Lipase inhibitor moieties having a free hydroxy group such as tetrahydro- esterastin (3,5-hydroxy-2-hexadeca-7,10-dienoic 1,3-lactone), 3,5-dihydroxy-2- hexylhexadeca-7,10-dienoic 1,3-lactone, 3,5-di-hydroxy-2-hexylhexadecanoic 1,3- lactone, and the like, are easily coupled to a polymer moiety having free hydroxy groups such as cellulose, chitosan and other polysaccharides having free hydroxyl groups.
  • One or both of the lipase inhibitor moiety and the polymer moiety may be derivitized to form part of the linking bridge prior to reacting with the other moiety.
  • the lipase inhibitor molecule may be condensed with a dihalide group or a terminal halide terminal acyl (acyl group may be protected with an acid group) to form an ether or ester linkage and then condensed with a polymer moiety having a free hydroxyl group as shown in polysaccharide chemistry.
  • a polymer moiety such as chitosan can be reacted with a compound such as a halomethylbenzoic acid ester, or the like, and de-esterified to present a free acid group which may be reacted to form a ketone, carboxamide or the like with the derivitized lipase inhibitor moiety.
  • one of the two moieties is reacted with an asymmetrical dihalide bridging group, such as an alkylene dihalide (e.g., 1,2-bromochloroethyl, 1,3-bromochloropropyl, and the like) in a molar ratio of 1 : 1 to etherize a free hydroxyl groups, replace a hydrogen atom on an amino group, or from a ketone with an acid group, and the resulting intermediate can then be reacted with the polymer moiety to form a ether group with a free alcohol group, replace a nitrogen atom on a amino group or form a ketone with an acid group.
  • an alkylene dihalide e.g., 1,2-bromochloroethyl, 1,3-bromochloropropyl, and the like
  • Particularly prefe ⁇ ed polymer moieties are polysaccharides having multiple free hydroxyl group which after coupling may optionally be sulfonated to render the lipase moiety itself a lipase inhibitor compound.
  • Etherification, amination and ketone formation procedures are well-known in the art and well within the routine skill of the ordinary practitioner.
  • other bridging groups and the techniques for binding a compound having a reactive functional group to a polymer moiety are well-known in the art.
  • the prefe ⁇ ed compounds also include their pharmaceutically acceptable isomers, hydrates, solvates, salts and prodrug derivatives.
  • the bridging group refers to a bifunctional chain or spacer group capable of reacting with one or more functional groups on a lipase inhibitor compound and then react with a second same or different functional group on a polymer compound in order to form a linked structure or conjugate between the two compounds.
  • the bond formed between the bridging group and each of the two compounds is preferably of a type that is resistant to cleavage by the digestive environment.
  • the bridging group is of the formula X-R-X, wherein R is a member selected from a straight-chained or branched alkyl group, a straight-chained or branched alkenyl group, a straight-chained or branched alkynyl group, a mono acyl group, a diacyl group and the like, and X is a functionally reactive group such as a halogen, under special reaction conditions as described hereinafter.
  • Particularly prefe ⁇ ed bridging groups form a diether or diacyl bridge that is resistant to cleavage by the digestive environment.
  • alkylene dichloride bridging group forming compounds are dichloromethane, 1 ,2-dichloroethane, 1,2- and 1,3-dichloropropane, 1,2-, 1,3- and 1,4- dichlorobutane, 1 ,2-bromochloroethane, 1,2-and 1,3-bromochloropropane, and the like.
  • acyldichloride bridging group forming compounds are oxalic acid dichloride, malonic acid dichloride, succinic acid dichloride, glutaric acid dichloride, adipic acid dichloride, pimelic acid dichloride, suberic acid dichloride, fumaric acid dichloride, malic acid dichloride, glutamic acid dichloride, terephthalic acid dichloride, isophthalic acid dichloride, and the like.
  • haloacyl bridging groups include chloromethylbenzoic acid or an ester thereof, 3-bromopropanoic acid, 2-chloroacetic acid, 6-bromohexanoic acid or an ester thereof, 12-bromododecanoic acid or an ester thereof, other n-haloalkanoic acids or esters thereof, and the like.
  • bridging group reagents are compounds such as epichlorhydrin, phosphorus oxychloride, and diphosphoryl tetrachloride, and the like.
  • Prefe ⁇ ed bridging groups are dihalide groups terminated with a bromo and a chlorine group, or groups terminated with an acyl group and a halogen group. Even more prefe ⁇ ed bridging groups are n-halo(preferably n-bromo)-C -C ⁇ 8 (preferably C 6 - Cj 4 ) alkanoic acids or esters thereof.
  • the reaction is performed by the slow addition of a bifunctional reagent such as a diacyl dichloride, an alkylene dichloride, or a bromosubstituted acyl ester compound, dissolved in a substantially water immiscible organic solvent, to an alkaline aqueous solution of the lipase inhibitor in a substantially 1 :1 molecular ratio.
  • a bifunctional reagent such as a diacyl dichloride, an alkylene dichloride, or a bromosubstituted acyl ester compound, dissolved in a substantially water immiscible organic solvent, to an alkaline aqueous solution of the lipase inhibitor in a substantially 1 :1 molecular ratio.
  • the reaction proceeds at the interface between the two immiscible solutions to provide an interfacial condensation and produce the polysaccharide derivative or analogue. It has been discovered that this reaction at the interface of the organic solution and the aqueous solution imparts a specific
  • bridging group reactant By appropriate selection of the type of bridging group reactant, different structural groups with various chemical properties can be incorporated into the resulting bridge and various types of lipase inhibitors can be connected to a nonabsorbable polymer moiety, such as a polysaccharide, and preferably to chitosan. Reaction temperatures and other reactions conditions, as well are reactant proportions are well within the skill of the ordinary polymer chemist practitioner. Other groups and modifications will be apparent to one of ordinary skill in the art from the above discussion.
  • the lipase inhibitor functionality of the coupled lipase inhibitors may be determined by well-known lipase inhibitor assays.
  • a therapeutically effective amount of the bound lipase inhibitor may be administered to a patient.
  • Additional fat binding polymers may optionally be added to the composition.
  • the invention provides a method for producing a compound of claim 1 , comprising reacting a compound of the formula:
  • the present invention provides a sports drink , snack, nutrient supplement, food or power which may be formulated to contain a lipase inhibiting therapeutically effective amount of the lipase inhibitor composition according to the invention.
  • the present invention relates to pharmaceutical compositions comprising a lipase inhibiting effective amount of at least one lipase inhibitor which is coupled to a digestively non-absorbable moiety.
  • a lipase inhibiting effective amount of at least one lipase inhibitor which is coupled to a digestively non-absorbable moiety.
  • a lipases coupled to a non-absorbable biocompatable, pharmaceutically acceptable polymer moiety, such as a polysaccharide, wherein the lipase is essentially non-absorbable by the digestive system of an animal such as a dog, cat, non-human primate or humans.
  • the pharmaceutical composition can be administrated to a patent prior to or within one
  • the present invention relates to a method for treating adiposity or obesity by administering to a patient before a fat-contain meal, or up to one hour after such a meal is consumed, an amount of at least one lipase inhibitor which is bound to a non-absorbable polymer moiety in an amount effective to inhibit the abso ⁇ tion of up to one-third of the dietary fat in such a meal .
  • a prefe ⁇ ed method comprises administering at one lipase inhibitor which is a member selected from the group consisting of esterastin, tetrahydro-esterastin (3,5-hydroxy- 2hexadeca-7, 10-dienoic 1 ,3-lactone), 3,5-dihydroxy-2-hexylhexadeca-7, 10-dienoic 1,3-lactone, 3,5-di-hydroxy-2-hexylhexadecanoic 1,3-lactone, and the like, wherein such lipase inhibitor is coupled to a non-absorbable biocompatable, pharmaceutically acceptable polymer moiety, such as a polysaccharide, to render the lipase non- absorbable by the digestive system of an animal such as a dog, cat, non-human primate or humans.
  • lipase inhibitor which is a member selected from the group consisting of esterastin, tetrahydro-esterastin (3,5-hydroxy- 2hexadeca-7, 10-dienoi
  • Particularly prefe ⁇ ed polysaccharides are at least one member selected from the group consisting of dextrans, molecular microcrystalhne cellulose, wheat bran, oat bran, defatted rice germ, alginic acid, pectin, amylopectin, chitin, crude cellulose, argar, chitosan and the like.
  • Particularly prefe ⁇ ed bound lipase inhibitors are lipase inhibitors bound via a derivatized nitrogen, acid or alcohol group to a derivatized alcohol, acid or amino group on the polymer moiety.
  • a diether bridge between the lipase inhibitor and the moiety which is derived from an alcohol group on the lipase and an alcohol group on the moiety, respectively reacting with a bridging group is the prefe ⁇ ed coupling of the lipase inhibitor to the moiety.
  • the compounds of this invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of this invention. Non-toxic and physiologically compatible salts are particularly useful although other less desirable salts may have use in the processes of isolation and purification.
  • salts described above Numerous methods are useful for the preparation of the salts described above and are known to those skilled in the art.
  • free acid or free base forms of a compound of one of the above compounds can be reacted with one or more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation, distillation or freeze drying.
  • the free acid or base form of the product may be passed over an ion exchange resin to form the desired salt or one salt form of the product may be converted to another using the same general process.
  • Prodrug Derivatives of Compounds This invention also encompasses prodrug derivatives of the compounds contained herein.
  • the term "prodrug” refers to a pharmacologically inactive derivative of a parent drug molecule that requires biotransformation, either spontaneous, acid/base reaction, or enzymatic, within the organism to release the active drug.
  • Prodrugs are variations or derivatives of the compounds of this invention which have groups cleavable under digestive system conditions. Prodrugs become the compounds of the invention which are pharmaceutically active in vivo, when they undergo solvolysis under physiological conditions or undergo enzymatic degradation.
  • Prodrug compounds of this invention may be called single, double, triple etc., depending on the number of biotransformation steps required to release the active drug within the organism, and indicating the number of functionalities present in a precursor-type form.
  • Prodrug forms often offer advantages of solubility, digestive compatibility, or delayed release in the mammalian organism (see, Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, CA, 1992).
  • Prodrugs commonly known in the art include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acids with a suitable alcohol, or amides prepared by reaction of the parent acid compound with an amine, or basic groups reacted to form an acylated base derivative.
  • the prodrug derivatives of this invention may be combined with other features herein taught to enhance bioavailability.
  • Formulations of the compounds of this invention are prepared for storage or administration by mixing the compound having a desired degree of purity with physiologically acceptable ca ⁇ iers, excipients, stabilizers etc., and may be provided in sustained release or timed release formulations.
  • Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co., (A.R. Gennaro edit. 1985).
  • Such materials are nontoxic to the recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate and other organic acid salts, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpy ⁇ olidinone, amino acids such as glycine, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween, Pluronics or polyethyleneglycol.
  • buffers such as phosphate, citrate, acetate and other organic acid salts
  • antioxidants such as
  • Dosage formulations of the compounds of this invention to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods. Formulations typically will be stored in lyophilized form or as an aqueous solution.
  • the pH of the preparations of this invention typically will be 3- 11, more preferably 5-9 and most preferably 7-8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of cyclic polypeptide salts.
  • Therapeutically effective dosages may be determined by either in vitro or in vivo methods. For each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required.
  • the range of therapeutically effective dosages will be influenced by the route of administration, the therapeutic objectives and the condition of the patient. Accordingly, it may be necessary for the therapist to titer the dosage and modify the means of administration as required to obtain the optimal therapeutic effect.
  • the determination of effective dosage levels that is, the dosage levels necessary to achieve the desired result, will be readily determined by one skilled in the art. Typically, applications of compound are commenced at lower dosage levels, with dosage levels being increased until the desired effect is achieved.
  • the compounds of the invention can be administered orally in an effective amount within the dosage range of about 10 to 400 mg/kg, preferably about 50 to 300 mg/kg and more preferably about 100 to 200 mg/kg per fat containing meal on a regimen in a single or 2 to 4 divided daily doses.
  • a prefe ⁇ ed dosage is an amount (e.g. about 100 to 200 mg/kg) that has a similar lipase inhibiting effect to the lipase inhibition of 120 mg (approximately 1-2 mg/kg dosage) of orally taken Orlistat.
  • the determination of such equivalent lipase inhibition can be determined via well-known lipase inhibition assays, and may be either an in vivo assay, an in vitro assay, or both.
  • the fat abso ⁇ tion properties of the lipophilic lipase inhibitor of the mvention can be observed by comparing the amount of anal oil discharged in a patient taking an lipase inhibitor equivalent amount of the lipase inhibitor according to the invention as compared to a patient taking only Orlistat.
  • the grooming of mice with anal oil is one comparison as compared to Orlistat or the actual comparison of anal discharge in animals or patients also will show a reduction in the amount of oily anal discharge when a lipophilic lipase inhibitor according to the invention is administered.
  • a compound or mixture of compounds of this invention is compounded with a physiologically acceptable vehicle, ca ⁇ ier, excipient, binder, preservative, stabilizer, dye, flavor etc., as called for by accepted pharmaceutical practice.
  • a physiologically acceptable vehicle ca ⁇ ier, excipient, binder, preservative, stabilizer, dye, flavor etc.
  • the amount of active ingredient in these compositions is such that a suitable dosage in the range indicated is obtained.
  • Typical adjuvants which may be inco ⁇ orated into tablets, capsules and the like are binders such as acacia, corn starch or gelatin, and excipients such as microcrystalline cellulose, disintegrating agents like corn starch or alginic acid, lubricants such as magnesium stearate, sweetening agents such as sucrose or lactose, or flavoring agents.
  • binders such as acacia, corn starch or gelatin
  • excipients such as microcrystalline cellulose, disintegrating agents like corn starch or alginic acid, lubricants such as magnesium stearate, sweetening agents such as sucrose or lactose, or flavoring agents.
  • lubricants such as magnesium stearate
  • sweetening agents such as sucrose or lactose
  • flavoring agents such as sucrose or lactose
  • flavoring agents such as sucrose or lactose
  • a dosage form is a capsule, in addition to the above materials it may also contain liquid carriers such as
  • dissolution or suspension of the active compound in a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired.
  • a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome
  • Buffers, preservatives, antioxidants and the like can be inco ⁇ orated according to accepted pharmaceutical practice.
  • the present invention includes pharmaceutical compositions comprising a pharmaceutically effective amount of the compounds of this mvention and a pharmaceutically acceptable carrier.
  • the present invention includes methods comprising using the above compounds and pharmaceutical compositions for preventing or treating disease states characterized by undesired lipid or fat abso ⁇ tion such as obesity, hyperlipaemia, atherosclerosis and ateioscherosis disorders of the blood coagulation process in mammals, or for stabilizing fats by preventing lipase function in stored fat products and samples.
  • the methods of this invention comprise administering the pharmaceutical composition in combination with an additional therapeutic agent such as an anticholesterol agent, appetite suppressant, metabolic stimulant and the like.
  • the prefe ⁇ ed compounds also include their pharmaceutically acceptable isomers, hydrates, solvates, salts and prodrug derivatives.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier excipient and an amount of at least one of the above described compounds according to the invention in a therapeutically effective amount with respect to limiting or preventing the abso ⁇ tion of some dietary fat.
  • the pharmaceutical composition comprises a therapeutically effective amount of slow-release lipoprotein lipase, preferably from a microbial or plant source, which selectively hydrolyzes terminal triglyceride groups in combination with an oil absorbing effective amount of polysaccharide such as chitosan, wherein the lipoprotein lipase is present in a ratio of less that 25% with respect to the oil absorbing polysaccharide.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier excipient, an amount of at least one of the above described compounds according to the invention in a therapeutically effective amount with respect to limiting or preventing the abso ⁇ tion of some dietary fat, and an oil absorbing effective amount of polysaccharide such as chitosan, wherein such lipase inhibitor is selectively effective to inhibit lipases other than lipases involved in the hydrolysis of terminal triglyceride groups and such lipase inhibitor does not substantially inhibit the abso ⁇ tion of vitamins A, D and E.
  • the present invention provides a method of using such compounds and pharmaceutical compositions as therapeutic agents for disease states in a mammal having at least one disorder that is due to undesired abso ⁇ tion of dietary fat or for reducing the effective caloric intake of a mammal who consumes dietary fat, which method may be useful in the treatment of undesired weight gain or obesity.
  • the compounds of this mvention also find utility as intermediates for producing therapeutic agents or as therapeutic agents for disease states in mammals which have disorders that are due to undesired abso ⁇ tion of dietary fat.
  • Methods for making starting materials may be found in U.S. Patent 4,931 ,463, which is inco ⁇ orated fully herein.
  • Prefe ⁇ ed oxetanones of the invention are compounds wherein R is methyl, ethyl, propyl, hexyl, decyl, hexadecyl, allyl and benzyl, and most preferably hexyl; R is hydrogen, methyl, ethyl, propyl, 2-butyl, isobutyl, benzyl and methylthio-ethyl, most preferably, hydrogen or isobutyl; R 2 is hydrogen, methyl or ethyl, most preferably hydrogen; n is 0 or 1 , and when t is 1 , then X is preferably attached to N via an amino acid, such as valine, alanine and the like, preferably alanine; and R 3 is preferably a straight or branched chained C ⁇ _ ⁇ 7 -alkyl group which is saturated or optionally interrupted by up to eight double or triple bonds, or R 3 is a straight or branched
  • the compounds produced according to the present invention may also be used as intermediates in the formation of compounds that may be administered in combination or in concert with other therapeutic or diagnostic agents.
  • the compounds produced by the intermediates according to the present invention may be co-administered along with other compounds typically prescribed for these conditions according to generally accepted medical practice such as other dietary maintenance medicaments and for diseases related to or impacted by the abso ⁇ tion of dietary fat.
  • the compounds produced from the intermediates according to the present invention may act in a synergistic fashion with other such medicaments.
  • Such compounds may also allow for reduced doses of other cholesterol inhibiting, appetite inhibiting and metabolic stimulating medicaments, and the like..
  • Such compounds can be utilized in vivo, ordinarily in mammals such as primates, (non-human and humans), sheep, horses, cattle, pigs, dogs, cats, rats and mice, or in vitro.
  • the starting materials used in above processes are commercially available from chemical vendors such as Aldrich, Sigma, Lancaster, TCI, and the like, or may be readily synthesized by known procedures, for example, by using procedures such as indicated above. Reactions are carried out in standard laboratory glassware and reaction vessels under reaction conditions of standard temperature and pressure, except where otherwise indicated, or is well-known in literature available in the art. Further, the above procedures of the claimed invention processes my be ca ⁇ ied out on a commercial scale by utilizing reactors and standard scale-up equipment available in the art for producing large amounts of compounds in the commercial environment. Such equipment and scale-up procedures are well-known to the ordinary practitioner in the field of commercial chemical production.
  • amino or acid functional groups may be protected by blocking groups to prevent undesired reactions with the amino group or acid group during certain procedures. Procedures for such protection and removal of protecting groups are routine in this art and well-known to the ordinary practitioner in this field.
  • Prefe ⁇ ed solvents are lower alkane ethers and alcohols; ethyl ether and isopropyl alcohol are prefe ⁇ ed for solvent extraction or recrystallization procedures.
  • Esters of carboxylic acid side groups may be formed that permit selective separation of the R and S enantiomers by solvent extraction or recrystallization.
  • D-alaninol is the prefe ⁇ ed enantiomer resolving agent, but other resolving agents or analogous procedures may be used, e.g., tartartic acid derivatives and the like.
  • the products may be further purified by column chromatography or other appropriate methods.
  • the above compounds produced according to the above invention may be isolated and further reacted to substitute a desired group for one or more of the hydrogen atoms on an amino group, on a free hydroxyl group or on a free acyl group by a coupling reaction with the desired group.
  • the compounds of this invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of this invention. Non-toxic and physiologically compatible salts are particularly useful although other less desirable salts may have use in the processes of isolation and purification.
  • a number of methods are useful for the preparation of the salts described above and are known to those skilled in the art. For example, reaction of the free acid or free base form of a compound of the structures recited above with one or more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation, distillation or freeze drying. Alternatively, the free acid or base form of the product may be passed over an ion exchange resin to form the desired salt or one salt form of the product may be converted to another using the same general process.
  • Diagnostic applications of the compounds of this invention will typically utilize formulations such as solution or suspension.
  • the compounds of this invention may be utilized in compositions such as tablets, capsules or elixirs for oral administration, sterile solutions or suspensions, and the like, or inco ⁇ orated into shaped articles.
  • Subjects in need of treatment (typically mammalian) using the compounds of this invention can be administered dosages that will provide optimal efficacy.
  • the dose and method of administration will vary from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concu ⁇ ent medication, overall clinical condition, the particular compounds employed, the specific use for which these compounds are employed, and other factors which those skilled in the medical arts will recognize.
  • Formulations of the compounds of this invention are prepared for storage or administration by mixing the compound having a desired degree of purity with physiologically acceptable carriers, excipients, stabilizers etc., and may be provided in sustained release or timed release formulations.
  • Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington 's Pharmaceutical Sciences, Mack Publishing Co., (A.R. Gennaro edit. 1985).
  • Such materials are nontoxic to the recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate and other organic acid salts, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpy ⁇ olidinone, amino acids such as glycine, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween, Pluronics or polyethyleneglycol.
  • buffers such as phosphate, citrate, acetate and other organic acid salts
  • antioxidants such as
  • Dosage formulations of the compounds of this invention to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods. Formulations typically will be stored in lyophilized form or as an aqueous solution.
  • the pH of the preparations of this invention typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of cyclic polypeptide salts.
  • the compounds of this invention are desirably inco ⁇ orated into food articles which may include fats to prevent their abso ⁇ tion.
  • the compounds of this invention may also be coupled with suitable polymers to enhance their therapeutic effects.
  • suitable polymers can include lipophilic polymers, such as polysaccharides and the like.
  • Therapeutically effective dosages may be determined by either in vitro or in vivo methods. For each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required.
  • the range of therapeutically effective dosages will naturally be influenced by the route of administration, the therapeutic objectives, and the condition of the patient.
  • the lipase inhibitor activity in view of the amount of fat consumed, must be individually determined for each inhibitor by methods well known in pharmacology. Accordingly, it may be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect.
  • the determination of effective dosage levels that is, the dosage levels necessary to achieve the desired result, will be within the ambit of one skilled in the art.
  • a lipase inhibitor compound or mixture of lipase inhibitor compounds of this mvention is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, dye, flavor etc., as called for by accepted pharmaceutical practice.
  • a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, dye, flavor etc. as called for by accepted pharmaceutical practice.
  • the amount of active ingredient in these compositions is such that a suitable dosage in the range indicated is obtained.
  • one or more other therapeutic ingredients such as a fat absorbing polysaccharide or fiber, a fat-specific lipase inhibitor or lipase, as well as other dietary agents may be utilized in therapeutically effective amounts.
  • Typical adjuvants which may be inco ⁇ orated into tablets, capsules and the like are a binder such as acacia, corn starch or gelatin, and excipient such as microcrystalline cellulose, a disintegrating agent like corn starch or alginic acid, a lubricant such as magnesium stearate, a sweetening agent such as sucrose or lactose, or a flavoring agent.
  • a dosage form is a capsule, in addition to the above materials it may also contain a liquid ca ⁇ ier such as water, saline, a fatty oil.
  • Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit.
  • Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. Buffers, preservatives, antioxidants and the like can be inco ⁇ orated according to accepted pharmaceutical practice.
  • the compounds of this invention may be used alone or in combination, or in combination with other therapeutic or diagnostic agents.
  • the compounds of this inventions may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice, such as
  • the compounds of this invention can be utilized in vivo, ordinarily in mammals such as non-human primates, humans, sheep, horses, cattle, pigs, dogs, cats, rats and mice, or in vitro.
  • Example 1 The following non-limiting examples are provided to better illustrate the present mvention.
  • Example 1 The following non-limiting examples are provided to better illustrate the present mvention.
  • the solid is suction filtered, suspended repeatedly in ethanol until all the soluble substances are removed to yield a crude product.
  • the crude product is sti ⁇ ed in an aqueous basic 1 N sodium hydroxide ethanol solution, which is then acidified with HC1 until neutral pH for chitosan.
  • the solid is washed twice with cold ethanol and cold water, and the solid is then dried to yield about 10 grams of ether functionalized chitosan. Analysis indicates that from 1% to 3% of the free hydroxyl groups on the chitosan polymeric backbone are etherified by the entry of the p-methylbenzoic acid group.
  • a colorless power of 3,5-dihydroxy-2-hexyl-hexadecanoic 1,3-lactone (6 g, produced as described on pages 11 and 12 of U.S. Patent 4,202,824) is dissolved in 500 mL of THF to which is added Boc-(L) 2-amino-4-methylpentanoic acid chloride (3 g, Boc-(L)-Leucine).
  • Boc-(L) 2-amino-4-methylpentanoic acid chloride (3 g, Boc-(L)-Leucine).
  • the reaction mixture is sti ⁇ ed and heated to reflux until HPLC indicates that the esterification is essentially complete.
  • Example 2 The BOC group of the product (6 mg) of Example 2 is removed by hydrogenation at room temperature in 120 mL of THF in the presence of 10% Pd/C. After hydrogenation is completed, the catalyst is filtered off and the filtrate is evaporated to yield a crude free amino group product, which is taken up in 100 mL of THF.
  • the functionalized chitosan product produced in Example 1 is taken up in 200 mL of THF and sti ⁇ ed while the crude free amino product is added dropwise at room temperature. The mixture is gradually heated to 40°C with stirring until HPLC indicates the formation of the carboxamide linked product. Yielded is 5-[2- ⁇ (4- chitosan methyl ether) benzoylamido ⁇ -4-methylvaleryloxy]-2-hexyl-hexadecanoic 1,3-lactone (about 15 grams).
  • the pH was then adjusted to about 8.5 by the addition of DIEA (disopropylethylamine) and the mixture was sti ⁇ ed at room temperature overnight.
  • the reaction mixture was reduced in volume by evaporated under vacuum to about 50% volume and 500 mL of hexane was added.
  • the mixture was filtered and the solid cake was washed with cold hexane three times and then with a cold ethanol/water (3:1) solution 3 times.
  • Lipase inhibition assays were performed essentially as follows using each of Compounds A and B.
  • a I L stock solution of IN NaOH was made and a 500 mL stock solution of 0.025 N NaOH was made by diluting a portion of the stock IN solution. Also a stock solution of 0.2 N HC1 was made.
  • a 100 mL TRIZMA solution (from Aldrich Lipase Assay Kit Cat. No. 800B) was diluted with 100 mL of denatured EtOH and 300 mL of water to form a 500 mL TEW solution.
  • Compound A from Example 6 (100 mg) was added to a portion of the 0.2 N HC1 stock solution and diluted to a final volume of 300 mL with the same HC1 stock solution to form a compound A stock solution.
  • Compound B from Example 7 was added to a portion of the 0.2 N HC1 stock solution and diluted to a final volume of 80 mL with the same HC1 stock solution to produce a compound B stock solution.
  • Aldrich Lipase PS Standard human lipase 3 mL x 3
  • Aldrich Product No. 8054 was diluted with isotonic saline solution to a 25 mL volume (Lipase #1 solution).
  • Product No. 32313 was diluted to a final volume of 25 mL with isotonic saline (Lipase #2 solution).
  • Aldrich Sigma Lipase Substrate Standard Cat. Product No. 62314 (3 x 100, 300 mL) was obtained to use as the lipid source.
  • sample control was 20 mL of the stock 0.2 N HC1 solution
  • sample A was 20 mL of the compound A stock solution
  • sample B was 20 mL of the compound B stock solution.
  • the pH was adjusted to about 8 with IN NaOH using a pH meter, whose reading was noted and recorded as a baseline reading after the pH adjustment.
  • the temperature was brought to 37.5°C and 1 mL of either Lipase #1 or Lipase #2 was added and a timer was started for 30 minutes.
  • the mixture was sti ⁇ ed and the temperature maintained between 35°C and 37°C. At the end of the time period, the mixture was sti ⁇ ed and triturated with 0.025 N NaOH.
  • the volume of NaOH solution used to return to the baseline pH reading was noted and recorded.
  • the percent inhibition by the Sample A or Sample B was calculated by subtracting the volume of NaOH used to return from baseline pH for either of Sample A or Sample B from the average volume of NaOH used to return from baseline pH for the control sample (three runs), the difference is divided by the average volume of NaOH used to return to baseline pH for the control sample, and the result was multiplied by 100% to obtain the percent inhibition of Sample A or Sample B (two runs each).
  • Oil binding assay were performed using each of Compounds A and B using the procedures essentially as follows.
  • Control 1 was obtained by adding 3 mL of olive oil to a 7 mL bottle, which showed the clear but light reflective oil.
  • Control 2 was obtained by adding 3 mL of olive oil to a 7 mL bottle and adding 10 drops of McCormick Schilling Red Food Coloring (RFC), which showed the oil insoluble food color at the bottom of the bottle and floating on top of the red food coloring is the 3 mL of light reflective olive oil.
  • ROC McCormick Schilling Red Food Coloring
  • Control 3 was obtained by adding 3 mL of olive oil to a 7 mL bottle and adding 3 mL of water followed by 5 drops RFC, which showed of the clear separation of the red aqueous layer on the bottom of the bottle and floating on top was the light reflective olive oil.
  • Control 4 was obtained by adding 1.5 g of olive oil to 1 g of chitosan (Natural Max Brand, greater than 90% deacylated chitin) and the two were mixed with a sti ⁇ er, followed by the addition of 4 mL of water and 5 drops of RFC, which showed the oil tightly bound to the chitosan in the bottom of the bottle, upon which was floating the aqueous red food color layer (a clean red meniscus with substantially no floating oil was observed).
  • chitosan Natural Max Brand, greater than 90% deacylated chitin
  • Control 5 was obtained by adding 1.5 g of olive oil to 1 g of cellulose (Avicel) and the two were mixed with a sti ⁇ er, followed by the addition of 4 mL of water and 5 drops of RFC, which showed some oil bound in the bottom to the cellulose, upon which was floating the aqueous red food color layer, further upon which was floating a clear layer of oil, about 3/4 mL (a clear floating oily layer meniscus was observed to show that cellulose does not tightly bind an excess of its weight in oil.
  • Control 6 was obtained by adding 8 g of olive oil to 1 g of chitosan and the two were mixed together with a sti ⁇ er, followed by the addition of 1 mL of water and 5 drops of RFC, which shows an hour-glass shape of oil bound by chitosan su ⁇ ounded in the middle of the bottle at the na ⁇ ow point with the aqueous red food color solution (chitosan binds oil and substantially excludes water from the bound mixture).
  • compound B was added to 8 times its weight of oil and sti ⁇ ed to a uniform consistency. The 1 mL of water was added and 5 drops of red food coloring were added. Upon mixing, the oil and compound B swelled to form a grainy gel-like consistency and uniformly absorbed the 1 mL of aqueous food coloring solution to form a homogenous gel composition, which was substantially homogeneously present even after 24 hours. This shows that compound B has the ability to bind oil and then absorb at least its weight in water to form grainy gel-like homogeneous mixture, and continues to tightly bind the oil while being hydrated with water.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Cette invention a trait à de nouveaux composés à base de dérivé d'oxétanone ainsi qu'à des procédés de production de ces dérivés qui se révèlent des plus utiles en tant qu'inhibiteurs de la lipase. Elle porte également sur des procédés de production de sels et de compositions pharmaceutiques ainsi que de composés renfermant au moins ce dérivé d'oxétanone ou ce sel. Elle concerne, de surcroît, des techniques d'utilisation de ces composés et compositions aux fins de l'inhibition des lipases.
PCT/US2000/029641 1999-10-27 2000-10-27 Derives d'oxetanone WO2001032616A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU12381/01A AU1238101A (en) 1999-10-29 2000-10-27 Oxetanone derivatives
CA002358921A CA2358921A1 (fr) 1999-10-29 2000-10-27 Derives d'oxetanone
KR1020017008352A KR20010108059A (ko) 1999-10-29 2000-10-27 옥세타논 유도체
IL14404500A IL144045A0 (en) 1999-10-29 2000-10-27 Oxetanone derivatives
EP00973938A EP1144377A4 (fr) 1999-10-29 2000-10-27 Derives d'oxetanone
MXPA01006755A MXPA01006755A (es) 1999-10-29 2000-10-27 Derivados de la oxetanona.
JP2001534769A JP2003524685A (ja) 1999-10-29 2000-10-27 オキセタノン誘導体
US09/901,166 US20020016307A1 (en) 1999-10-27 2001-07-09 Pharmaceutical composition with both a lipase inhibitor and a lipophilic polysaccharide and an improved method for treating adiposity

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US09/431,551 1999-10-29
US09/431,551 US6235305B1 (en) 1999-10-29 1999-10-29 Essentially nonabsorbable lipase inhibitor derivatives, pharmaceutical compositions and methods of use therefor
US16596099P 1999-11-17 1999-11-17
US06/165,960 1999-11-17
US61832800A 2000-07-18 2000-07-18
US09/618,328 2000-07-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US61832800A Continuation-In-Part 1999-10-27 2000-07-18

Publications (2)

Publication Number Publication Date
WO2001032616A2 true WO2001032616A2 (fr) 2001-05-10
WO2001032616A3 WO2001032616A3 (fr) 2002-01-10

Family

ID=27389199

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/029592 WO2001032670A1 (fr) 1999-10-29 2000-10-27 Dérivés d'oxétanone
PCT/US2000/029641 WO2001032616A2 (fr) 1999-10-27 2000-10-27 Derives d'oxetanone

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029592 WO2001032670A1 (fr) 1999-10-29 2000-10-27 Dérivés d'oxétanone

Country Status (8)

Country Link
EP (1) EP1144377A4 (fr)
JP (1) JP2003524685A (fr)
CN (1) CN1342169A (fr)
AU (2) AU1347701A (fr)
CA (1) CA2358921A1 (fr)
IL (1) IL144045A0 (fr)
MX (1) MXPA01006755A (fr)
WO (2) WO2001032670A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US8039508B2 (en) 2001-06-06 2011-10-18 Hoffmann-La Roche Inc. Lipase inhibiting composition

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074822B2 (en) 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
DE102004009076A1 (de) * 2004-02-23 2005-10-27 Solvay Pharmaceuticals Gmbh Alkylcarbamat-substituierte β-Lactone, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189438A (en) * 1977-02-08 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Physiologically active substance esterastin
US4202824A (en) * 1978-05-25 1980-05-13 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Physiologically active derivatives of esterastin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1328881C (fr) * 1984-12-21 1994-04-26 Pierre Barbier Procede pour la fabrication d'oxetanones
CA1270837A (fr) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
IL97148A (en) * 1990-02-26 1996-11-14 Hoffmann La Roche Oxtanones, the process for their preparation and the pharmaceutical preparations containing them
CA2128044C (fr) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Compositions pharmaceutiques comportant un glucosidase et/ou un inhibiteur d'amylase, et un inhibiteur des lipases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189438A (en) * 1977-02-08 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Physiologically active substance esterastin
US4202824A (en) * 1978-05-25 1980-05-13 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Physiologically active derivatives of esterastin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1144377A1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US8039508B2 (en) 2001-06-06 2011-10-18 Hoffmann-La Roche Inc. Lipase inhibiting composition
US8343543B2 (en) 2001-06-06 2013-01-01 Hoffmann-La Roche Inc. Lipase inhibiting composition

Also Published As

Publication number Publication date
JP2003524685A (ja) 2003-08-19
CN1342169A (zh) 2002-03-27
WO2001032670A1 (fr) 2001-05-10
AU1347701A (en) 2001-05-14
EP1144377A4 (fr) 2002-05-02
WO2001032616A3 (fr) 2002-01-10
MXPA01006755A (es) 2003-05-15
IL144045A0 (en) 2002-04-21
AU1238101A (en) 2001-05-14
CA2358921A1 (fr) 2001-05-10
EP1144377A1 (fr) 2001-10-17

Similar Documents

Publication Publication Date Title
JPH09503771A (ja) 治療剤
CN101289438B (zh) 3-(3'-羟基)-丁基苯酞酯及其制法和用途
US6342519B2 (en) Oxetanone derivatives
CN102459210A (zh) 芳基磺酰胺ccr3拮抗剂
EP1144377A1 (fr) Derives d'oxetanone
US6348492B1 (en) Oxetanone derivatives
CN104592204B (zh) 达比加群衍生物及其制备方法和用途
US6235305B1 (en) Essentially nonabsorbable lipase inhibitor derivatives, pharmaceutical compositions and methods of use therefor
CN103270033B (zh) C-芳基葡糖苷衍生物及其制备方法和应用
CN110577573B (zh) Yigs五肽修饰的s,r-七环醛,其合成,活性和应用
JP2022505033A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
WO2022092294A1 (fr) Nouveau traitement et nouvelle prévention de maladies liées à la sarcopénie
CN1128999A (zh) 杂环化合物
CN105272984B (zh) 吡唑并[3,4-d]嘧啶-4-酮衍生物、其制备方法和应用
US6392061B1 (en) Process for making (2S, 3S, 5S) oxetanone derivatives
KR20010108059A (ko) 옥세타논 유도체
CN1711247A (zh) 塞来考昔的前药
JP2711939B2 (ja) ６−クロロ−５−フルオロ−３−（２−テノイル）−２−オキシンドール−１−カルボキサミドのリジン塩
JPH1067804A (ja) キトサン誘導体およびその製造法並びにその用途
JPH072867A (ja) ビオチンアミド誘導体の製造方法及び、それらを含有する糖尿病及び糖尿病合併症の治療剤
JP3406334B2 (ja) チロシン特異的リン酸化酵素阻害剤及び制癌剤
CN116870176A (zh) PSMA靶向的PSMA-PARPi偶联物及制备方法和应用
CN113185492A (zh) 一种新型四氢苯并噻吩-2-尿素衍生物的合成及其用途
CN105439877B (zh) 带正电荷的水溶性二氟尼柳及相关化合物的前药
JP2002516611A (ja) 結晶性（−）−３ｒ，４ｒ−トランス−７−メトキシ−２，２−ジメチル−３−フェニル−４−｛４−〔２−（ピロリジン−１−イル）エトキシ〕フェニル｝クロマン水素マレエート

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00804391.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2358921

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 144045

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2001 534769

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/006755

Country of ref document: MX

Ref document number: 1020017008352

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000973938

Country of ref document: EP

Ref document number: 12381/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000973938

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2358921

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 2000973938

Country of ref document: EP